DNA

KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditions

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical…

2 years ago

IO Biotech to Participate in the Jefferies London Healthcare Conference

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

2 years ago

Senti Bio Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company…

2 years ago

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA),…

2 years ago

Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…

2 years ago

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

2 years ago

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…

2 years ago

IRADIMED CORPORATION to Hold 2022 Third Quarter Financial Results Conference Call on November 3rd

WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its…

2 years ago

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…

2 years ago

HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science…

2 years ago